9.1 Ambulatory Infections & Outpatient Antimicrobial Stewardship
Key Takeaways
- Acute uncomplicated cystitis first-line therapies are nitrofurantoin 100 mg BID x 5 days (safe if CrCl >= 30 mL/min), TMP-SMX DS 1 tab BID x 3 days (if local resistance < 20%), and fosfomycin 3 g single dose; avoid fluoroquinolones for uncomplicated cystitis.
- Outpatient acute pyelonephritis requires oral ciprofloxacin (500 mg BID x 7 days) or levofloxacin (750 mg daily x 5 days); if local fluoroquinolone resistance exceeds 10%, an initial dose of IV ceftriaxone 1 g or consolidated aminoglycoside is mandatory.
- Community-acquired pneumonia (CAP) in outpatients without comorbidities is treated with amoxicillin 1 g TID, doxycycline 100 mg BID, or a macrolide (only if local pneumococcal resistance is < 25%); outpatients with comorbidities require beta-lactam combination therapy (e.g., Augmentin + macrolide/doxycycline) or respiratory fluoroquinolone monotherapy.
- Streptococcal pharyngitis requires 10 days of oral penicillin V or amoxicillin (cephalexin or azithromycin in penicillin allergy), whereas acute rhinosinusitis warrants watchful waiting up to 10 days before initiating amoxicillin/clavulanate.
- Non-purulent cellulitis is primarily treated with anti-streptococcal beta-lactams (cephalexin, cefadroxil, dicloxacillin x 5 days), whereas purulent SSTIs mandate incision and drainage, adding MRSA-active coverage (TMP-SMX, doxycycline, or clindamycin) for systemic or extensive disease.
Ambulatory Infections & Outpatient Antimicrobial Stewardship
Executive Summary: Up to 50% of outpatient antibiotic prescriptions in the United States are unnecessary or inappropriate, contributing directly to selective antimicrobial resistance, Clostridioides difficile colitis, and preventable adverse drug events. Ambulatory care pharmacists play a pivotal role in implementing the CDC Core Elements of Outpatient Antibiotic Stewardship (Commitment, Action for policy/practice, Tracking and reporting, Education and expertise) to ensure guideline-concordant antimicrobial selection, precise dosing, and minimal effective durations of therapy for urinary tract, respiratory, and dermatologic infections.
1. Outpatient Antimicrobial Stewardship Core Elements
The CDC outlines four foundational pillars for outpatient antibiotic stewardship programs (ASPs) across primary care clinics, urgent care centers, and community health centers:
CDC Core Elements in Practice
- Commitment: Demonstrate dedication to optimizing antibiotic prescribing and patient safety through visible public commitment posters in clinical examination rooms, establishing clinic-wide antibiograms, and designating a physician and clinical pharmacy stewardship lead.
- Action for Policy & Practice: Implement at least one evidence-based policy or clinical intervention:
- Delayed Prescribing / Post-Dated Prescriptions: Providing a prescription with instructions to fill only if symptoms worsen or fail to improve after a defined observation window (e.g., watchful waiting for acute otitis media or acute rhinosinusitis).
- Communication Strategies: Using positive framing and "symptom-focused" treatment plans for viral upper respiratory infections rather than simply stating "you do not need an antibiotic."
- Standardized Clinical Decision Support (CDS): Embedding order sets, duration hard-stops, and local antibiograms into the Electronic Health Record (EHR).
- Tracking & Reporting: Systematically audit individual clinician prescribing patterns (e.g., percentage of bronchitis or viral URIs prescribed antibiotics), benchmark providers against high-performing peers, and feed data back during clinical peer reviews.
- Education & Expertise: Provide ongoing educational resources to clinicians and patients regarding realistic timelines for viral symptom resolution and the risks of unnecessary antibiotic exposure.
2. Urinary Tract Infections: Acute Uncomplicated Cystitis vs. Pyelonephritis
Urinary tract infections (UTIs) represent one of the most common ambulatory care presentations. Clinical management requires differentiating lower tract infection (acute uncomplicated cystitis) from upper tract parenchymal infection (acute pyelonephritis).
Acute Uncomplicated Cystitis (AUC)
Defined as lower urinary tract infection (dysuria, frequency, urgency, suprapubic pain) occurring in premenopausal, non-pregnant females with structurally and functionally normal genitourinary tracts and no systemic symptoms (fever, chills, flank pain, costovertebral angle [CVA] tenderness).
| Guideline First-Line Regimen | Dose & Route | Duration | Clinical Nuances & Pharmacokinetics |
|---|---|---|---|
| Nitrofurantoin monohydrate / macrocrystals (Macrobid) | 100 mg PO BID | 5 days | Highly active against E. coli; safe and effective if CrCl ≥ 30 mL/min (2015 Beers/IDSA update lowered cutoff from 60 mL/min). Ineffective for pyelonephritis due to lack of renal parenchymal and tissue penetration. |
| Trimethoprim / Sulfamethoxazole (TMP-SMX DS) | 1 DS tablet (160/800 mg) PO BID | 3 days | First-line ONLY if local E. coli resistance is < 20% and patient has not used it in the prior 3 months. Risk of hyperkalemia, serum creatinine elevation (via inhibition of tubular secretion), and severe dermatologic reactions. |
| Fosfomycin tromethamine | 3 g oral powder sachet | Single dose | Dissolved in 3–4 oz cold water. Broad coverage including ESBL-producing E. coli. Lower clinical cure rates compared to nitrofurantoin and TMP-SMX, but maximizes compliance. |
Second-Line & Inappropriate Cystitis Regimens
- Oral Beta-Lactams (Second-Line): Cephalexin 500 mg PO BID-QID x 5–7 days, Cefdinir 300 mg PO BID x 5–7 days, or Amoxicillin/Clavulanate 500/125 mg PO BID x 5–7 days. Beta-lactams exhibit lower efficacy and higher recurrence rates than first-line agents.
- DO NOT USE Fluoroquinolones (Ciprofloxacin, Levofloxacin): The FDA and IDSA issue strong warnings against using fluoroquinolones for uncomplicated cystitis due to the unfavorable risk-to-benefit ratio (tendonitis/tendon rupture, peripheral neuropathy, CNS toxicities, QT prolongation, and aortic dissection) when safer alternatives exist.
- Symptomatic Adjuncts: Phenazopyridine (Pyridium) 100–200 mg PO TID after meals can be used for a maximum of 2 days to alleviate severe dysuria. Counsel patients regarding reddish-orange discoloration of urine and staining of contact lenses; phenazopyridine has no antimicrobial activity.
Acute Pyelonephritis (Outpatient Management)
Characterized by fever (>38°C / 100.4°F), flank pain, costovertebral angle (CVA) tenderness, nausea, and vomiting, with or without lower urinary tract symptoms. Mild-to-moderate cases can be managed outpatient if the patient can tolerate oral medications and is hemodynamically stable.
- Fluoroquinolones (Preferred Oral Regimens):
- Ciprofloxacin: 500 mg PO BID x 7 days (or Ciprofloxacin ER 1000 mg PO daily x 7 days).
- Levofloxacin: 750 mg PO daily x 5 days.
- Initial IV Dose Rule: If local fluoroquinolone resistance in E. coli exceeds 10%, administer an initial intravenous dose of a long-acting parenteral agent (Ceftriaxone 1 g IV or a consolidated aminoglycoside dose) in clinic prior to starting oral fluoroquinolones.
- Alternative Pyelonephritis Regimens:
- TMP-SMX DS: 1 tablet PO BID x 14 days (if susceptibility is known; if empirical, give initial IV Ceftriaxone 1 g dose).
- Oral Beta-Lactams: Less effective than fluoroquinolones; if used, ALWAYS precede with an initial dose of IV Ceftriaxone 1 g and treat for a total of 10 to 14 days.
3. Community-Acquired Pneumonia (CAP): 2019 ATS/IDSA Guidelines
The 2019 American Thoracic Society / Infectious Diseases Society of America (ATS/IDSA) CAP guidelines stratify outpatient management strictly by the presence or absence of underlying chronic comorbidities.
Clinical Comorbidity Definition
Chronic heart disease (heart failure, CAD, cardiomyopathy; excluding hypertension alone), chronic pulmonary disease (COPD, asthma, bronchiectasis), chronic liver disease, chronic renal disease, diabetes mellitus, alcoholism, active malignancy, or asplenia.
┌────────────────────────────────────────────────────────────────────────┐
│ CAP OUTPATIENT REGIMEN SELECTION │
├──────────────────────────────────┬─────────────────────────────────────┤
│ NO COMORBIDITIES │ WITH COMORBIDITIES │
│ • Amoxicillin 1 g PO TID (5d) │ • Beta-Lactam + Macrolide/Doxy (5d) │
│ • Doxycycline 100 mg PO BID (5d) │ - Augmentin 875/125 or 2000/125 mg│
│ • Macrolide (only if <25% resist)│ - Cefpodoxime 200mg / Cefuroxime │
│ - Azithromycin 500mg then 250mg│ PLUS Azithro 500/250mg or Doxy │
│ - Clarithromycin 500mg BID │ OR │
│ │ • Respiratory FQ Monotherapy (5d) │
│ │ - Levofloxacin 750 mg PO daily │
│ │ - Moxifloxacin 400 mg PO daily │
└──────────────────────────────────┴─────────────────────────────────────┘
Outpatient CAP Regimens in Detail
1. Outpatients WITHOUT Comorbidities
- Amoxicillin: 1 g PO three times daily (TID) x 5 days (provides high-dose target attainment against Streptococcus pneumoniae).
- Doxycycline: 100 mg PO twice daily (BID) x 5 days (covers S. pneumoniae, Mycoplasma pneumoniae, Chlamydia pneumoniae, and Legionella).
- Macrolide Monotherapy (Conditional): Azithromycin 500 mg on day 1, then 250 mg daily on days 2–5 OR Clarithromycin 500 mg BID (or 1000 mg ER daily) x 5 days. CRITICAL RESTRICTION: Macrolide monotherapy is recommended ONLY in regions where pneumococcal macrolide resistance is documented to be < 25%. In the vast majority of US communities, macrolide resistance exceeds 30–40%, making empiric macrolide monotherapy inappropriate.
2. Outpatients WITH Comorbidities
Outpatients with underlying comorbidities require broader coverage against beta-lactamase-producing organisms (Haemophilus influenzae, Moraxella catarrhalis), enteric Gram-negative bacilli, and resistant pneumococci:
- Option A: Combination Therapy (Beta-Lactam + Atypical Coverage)
- Beta-Lactam Base: Amoxicillin/Clavulanate 875/125 mg PO BID, Amoxicillin/Clavulanate ER 2000/125 mg PO BID, Cefpodoxime 200 mg PO BID, or Cefuroxime axetil 500 mg PO BID.
- PLUS Atypical Agent: Azithromycin 500 mg day 1 then 250 mg daily (or Clarithromycin 500 mg BID) OR Doxycycline 100 mg PO BID.
- Option B: Monotherapy with Respiratory Fluoroquinolone
- Levofloxacin: 750 mg PO once daily x 5 days.
- Moxifloxacin: 400 mg PO once daily x 5 days.
- Gemifloxacin: 320 mg PO once daily x 5 days.
- Clinical Pearl: Ciprofloxacin is NOT a respiratory fluoroquinolone due to inadequate S. pneumoniae activity and must never be used for CAP.
Duration of Therapy
Treat for a minimum of 5 days. The patient must achieve clinical stability (afebrile for 48–72 hours, heart rate < 100 bpm, respiratory rate < 24 bpm, systolic BP ≥ 90 mmHg, O₂ saturation ≥ 92% on room air, able to maintain oral intake) prior to discontinuing therapy.
4. Upper Respiratory Infections & Skin/Soft Tissue Infections (SSTI)
Acute Bacterial Rhinosinusitis (ABRS)
Over 90% of acute rhinosinusitis cases are viral. Guidelines from the IDSA recommend antimicrobial therapy only when clinical criteria distinguish bacterial infection from viral illness:
- Persistent Symptoms: Nasal discharge and facial pressure lasting ≥ 10 days without any clinical improvement.
- Severe Onset: High fever (≥ 39°C / 102°F) accompanied by purulent nasal discharge and facial pain lasting ≥ 3–4 consecutive days at disease onset.
- Double Sickening: Acute worsening of fever, headache, or nasal discharge following initial improvement of a typical viral URI (lasting 5–6 days).
ABRS Pharmacotherapy
- Watchful Waiting: For uncomplicated cases meeting 10-day criteria without severe toxicity, symptomatic therapy (nasal saline irrigation, intranasal corticosteroids, analgesics) and watchful waiting for an additional 7 days is safe and effective.
- First-Line Antibiotic: Amoxicillin/Clavulanate 875/125 mg PO BID x 5–7 days in adults. High-dose Augmentin (2000/125 mg PO BID) is indicated if age ≥ 65, recent antibiotic use within 30 days, prior hospitalization within 5 days, or immunocompromise.
- Why not Amoxicillin alone? Beta-lactamase production in H. influenzae and M. catarrhalis reaches 30–50% and >90%, respectively.
- Penicillin Allergy: Doxycycline 100 mg PO BID x 5–7 days or a respiratory fluoroquinolone (Levofloxacin 500 mg daily). Avoid macrolides and TMP-SMX due to high rates of pneumococcal resistance.
Streptococcal Pharyngitis (Group A Strep / Streptococcus pyogenes)
Pharyngitis is predominantly viral. Testing with a Rapid Antigen Detection Test (RADT) or throat culture is required before initiating antibiotics. Treatment prevents acute rheumatic fever, reduces symptom duration, and prevents suppurative complications.
| Regimen | Dose | Duration | Clinical Notes |
|---|---|---|---|
| Penicillin V Potassium (Preferred) | 500 mg PO BID to TID | 10 days | Narrow spectrum, highly effective, zero documented GAS resistance. |
| Amoxicillin | 500 mg PO BID or 1000 mg PO daily | 10 days | Superior palatability in suspensions; equivalent efficacy. |
| Benzathine Penicillin G | 1.2 million units IM | Single dose | Indicated for patients unable to complete 10-day oral course. |
| Cephalexin or Cefadroxil | Cephalexin 500 mg PO BID | 10 days | First-line in patients with non-severe (non-IgE mediated) penicillin allergy. |
| Azithromycin or Clarithromycin | Azithromycin 500 mg day 1, then 250 mg daily | 5 days (Azithro) / 10d (Clarithro) | Reserved for severe IgE-mediated penicillin allergy (anaphylaxis). |
| Clindamycin | 300 mg PO TID | 10 days | Alternative for severe penicillin allergy; highly active against GAS. |
Skin and Soft Tissue Infections (SSTI)
┌────────────────────────────────────────────────────────────────────────┐
│ SSTI CLASSIFICATION & THERAPY │
├──────────────────────────────────┬─────────────────────────────────────┤
│ NON-PURULENT SSTI │ PURULENT SSTI │
│ (Cellulitis, Erysipelas) │ (Abscess, Carbuncle, Furuncle) │
│ • Predominant: Group A Strep/MSSA│ • Predominant: S. aureus / MRSA │
│ • PRIMARY: Oral Beta-Lactams │ • PRIMARY: Incision & Drainage (I&D)│
│ - Cephalexin 500 mg QID (5d) │ • ADD ORAL MRSA ANTIBIOTICS IF: │
│ - Cefadroxil 500 mg BID (5d) │ - Systemic signs (fever, SIRS) │
│ - Dicloxacillin 500 mg QID (5d)│ - Multiple abscesses, large >2cm │
│ • Pen Allergy: Clindamycin 300mg │ - Immunocompromised / comorbidities│
│ │ • REGIMENS (5 Days): │
│ │ - TMP-SMX DS 1-2 tabs PO BID │
│ │ - Doxycycline 100 mg PO BID │
│ │ - Clindamycin 300-450 mg PO TID │
└──────────────────────────────────┴─────────────────────────────────────┘
- Non-Purulent SSTI (Cellulitis): Treat with oral agents active against streptococci and MSSA for 5 days (extend if clinical response is delayed). Cephalexin 500 mg PO QID is standard. MRSA coverage is NOT routinely required for typical non-purulent cellulitis unless systemic toxicity, penetrating trauma, or prior MRSA colonization is present.
- Purulent SSTI (Cutaneous Abscess): Incision and Drainage (I&D) is the definitive therapeutic intervention. For simple, small (< 2 cm) single abscesses without surrounding cellulitis or systemic signs, I&D alone is curative without antibiotics. If systemic signs, multiple sites, or severe surrounding erythema are present, add 5 days of oral MRSA coverage (TMP-SMX DS 1–2 tabs BID, Doxycycline 100 mg BID, or Clindamycin 300–450 mg TID).
A 32-year-old female presents to an ambulatory primary care clinic complaining of a 2-day history of burning with urination, urinary frequency, and suprapubic discomfort. She has no fever, chills, nausea, vomiting, or flank pain. Physical examination shows no costovertebral angle tenderness. A point-of-care urinalysis reveals positive leukocyte esterase and positive nitrites. Her medical history is unremarkable, and her baseline serum creatinine is 0.7 mg/dL (estimated CrCl 105 mL/min). She has no known drug allergies. The clinic's regional antibiogram reports 28% resistance of Escherichia coli to trimethoprim/sulfamethoxazole. Which of the following antimicrobial regimens represents the most appropriate first-line treatment for this patient?
A 66-year-old male with a history of COPD, Type 2 Diabetes Mellitus, and Stage 3a Chronic Kidney Disease presents to an outpatient clinic with a 3-day history of productive cough with purulent sputum, low-grade fever (38.1°C / 100.6°F), and mild exertional dyspnea. Chest radiography confirms a right lower lobe consolidation consistent with community-acquired pneumonia (CAP). Physical exam reveals crackles in the right lung base, blood pressure 128/78 mmHg, heart rate 88 bpm, and room air O2 saturation 94%. He has no drug allergies and has not received antibiotics in the past 6 months. In accordance with the 2019 ATS/IDSA CAP guidelines, which of the following represents the most appropriate empiric outpatient oral regimen?
A 44-year-old male presents to urgent care with a 3 cm fluctuant, tender, erythematous swelling on his right thigh consistent with a cutaneous abscess. He is afebrile (36.8°C / 98.2°F), vitals are stable, and there is a 1 cm rim of surrounding erythema without systemic toxicity. The clinician performs a successful incision and drainage (I&D), expressing 10 mL of purulent material. The patient has no underlying comorbidities or immunosuppression. Which of the following is the most appropriate next step in management for this patient's skin and soft tissue infection?